NASDAQ:IMMY - Imprimis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.22 -0.17 (-3.15 %)
(As of 12/18/2018 04:00 PM ET)
Previous Close$5.39
Today's Range$5.00 - $5.47
52-Week Range$1.45 - $6.50
Volume9,757 shs
Average Volume435,345 shs
Market Capitalization$135.71 million
P/E Ratio-8.50
Dividend YieldN/A
Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive IMMY News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMMY
Previous Symbol


Debt-to-Equity Ratio2.84
Current Ratio1.13
Quick Ratio0.88


Trailing P/E Ratio-8.50
Forward P/E Ratio7.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.77 million
Price / Sales4.54
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.13 per share
Price / Book40.15


EPS (Most Recent Fiscal Year)($0.60)
Net Income$-11,980,000.00
Net Margins-16.81%
Return on Equity-231.16%
Return on Assets-25.18%


Outstanding Shares23,280,000
Market Cap$135.71 million

Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) posted its quarterly earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.03. The specialty pharmaceutical company earned $10.74 million during the quarter. Imprimis Pharmaceuticals had a negative return on equity of 231.16% and a negative net margin of 16.81%. View Imprimis Pharmaceuticals' Earnings History.

When is Imprimis Pharmaceuticals' next earnings date?

Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Imprimis Pharmaceuticals.

What price target have analysts set for IMMY?

2 brokerages have issued 12-month price objectives for Imprimis Pharmaceuticals' shares. Their predictions range from $10.00 to $11.50. On average, they expect Imprimis Pharmaceuticals' stock price to reach $10.75 in the next year. This suggests a possible upside of 105.9% from the stock's current price. View Analyst Price Targets for Imprimis Pharmaceuticals.

What is the consensus analysts' recommendation for Imprimis Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Imprimis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Imprimis Pharmaceuticals.

Has Imprimis Pharmaceuticals been receiving favorable news coverage?

News coverage about IMMY stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Imprimis Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near future.

Who are some of Imprimis Pharmaceuticals' key competitors?

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark L. Baum, Founder, CEO & Director (Age 45)
  • Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 36)
  • Mr. John P. Saharek, Chief Commercial Officer (Age 58)
  • Mr. David Moufarrège, VP of Technology
  • Mr. Pramod Sharma Ph.D., VP of Quality

Who are Imprimis Pharmaceuticals' major shareholders?

Imprimis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (7.70%), Vanguard Group Inc (3.14%), Vanguard Group Inc. (3.14%), Granite Investment Partners LLC (1.17%), JPMorgan Chase & Co. (0.56%) and Renaissance Technologies LLC (0.44%). Company insiders that own Imprimis Pharmaceuticals stock include Andrew R Boll, Mark L Baum, Richard L Md Lindstrom and Robert J Kammer. View Institutional Ownership Trends for Imprimis Pharmaceuticals.

Which major investors are selling Imprimis Pharmaceuticals stock?

IMMY stock was sold by a variety of institutional investors in the last quarter, including Corrado Advisors LLC. View Insider Buying and Selling for Imprimis Pharmaceuticals.

Which major investors are buying Imprimis Pharmaceuticals stock?

IMMY stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Renaissance Technologies LLC, Granite Investment Partners LLC, JPMorgan Chase & Co., Vanguard Group Inc and Vanguard Group Inc.. Company insiders that have bought Imprimis Pharmaceuticals stock in the last two years include Andrew R Boll, Mark L Baum and Richard L Md Lindstrom. View Insider Buying and Selling for Imprimis Pharmaceuticals.

How do I buy shares of Imprimis Pharmaceuticals?

Shares of IMMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Imprimis Pharmaceuticals' stock price today?

One share of IMMY stock can currently be purchased for approximately $5.22.

How big of a company is Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals has a market capitalization of $135.71 million and generates $26.77 million in revenue each year. The specialty pharmaceutical company earns $-11,980,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. Imprimis Pharmaceuticals employs 128 workers across the globe.

What is Imprimis Pharmaceuticals' official website?

The official website for Imprimis Pharmaceuticals is

How can I contact Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected]

MarketBeat Community Rating for Imprimis Pharmaceuticals (NASDAQ IMMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  315
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel